<DOC>
	<DOC>NCT02114658</DOC>
	<brief_summary>The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).</brief_summary>
	<brief_title>Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or metastatic MTC (medullary thyroid carcinoma) Not a candidate for surgery or radiotherapy with curative intent Histologically or cytologically confirmed ATC or MTC Measurable or nonmeasurable disease (but clinically evaluable) according to RECIST 1.1. Age &gt;= 18 years Adequate bone marrow, liver and renal function to be conducted within 14 days prior to treatment Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 Life expectancy of at least 12 weeks Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma Prior anticancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth factor) receptors or other targeted agents Prior chemotherapy for thyroid cancer (only one regimen is allowed) Major surgery, open biopsy, or significant traumatic injury within 30 days prior to enrollment in the study. Subjects with tracheal, bronchial or esophageal infiltration with significant risk of bleeding but without having received local treatment prior to enrollment in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anaplastic and medullary thyroid carcinoma</keyword>
	<keyword>Thyroid Neoplasms</keyword>
</DOC>